Navigation Links
New study finds adverse effects of estrogen replacement therapy are related to the dose
Date:4/7/2008

SAN DIEGO, CA Recent clinical trials indicate that estrogen replacement therapy (ERT) may increase the risk of cardiovascular diseases. A new study in mice has examined whether adverse effects of ERT are related to the doses used. The study found that moderate and high doses of ERT increased problems in the kidney and heart. These results suggest that ERT dosage may be an important determinant in a womans overall health.

The study, Dose-Response Effect of Estrogen on the Kidney and Heart, was conducted by Xiaomei Meng, Martin Antonio DAmbrosio, Tang-Dong Liao and Xiao-Ping Yang. The researchers are members of the Hypertension and Vascular Research Division of Henry Ford Hospital, Detroit, MI. Dr. Yang is presenting her teams findings during the 121st Annual Meeting of the American Physiological Society (APS; www.the-APS.org/press/), part of the Experimental Biology 2008 scientific conference

Background

The frequency of cardiovascular disease (CVD) and the deaths that are associated with it are much lower in premenopausal women than in men of similar age. This female gender advantage becomes far less or disappears with increased age and reduced estrogen levels after menopause, suggesting that ovarian hormones, most likely estrogen, protect women against CVD.

Studies have show that postmenopausal women who receive hormonal replacement therapy (HRT) have a lower incidence of CVD and die less frequently than those not receiving HRT. As a result, HRT has commonly been used for prevention of CVD in postmenopausal women. However, recently published data by the Heart and Estrogen/Progestin Replacement Study (HERS) and the Womens Health Initiative (WHI) showed an unfavorable effect of HRT on the risk and events of CVD in women. But while the data were convincing, there are other considerations such as composition of the drugs, dosage, time when HRT was initiated, age, and pre-existing risk factors for CVD, which may have affected the outcome of HERS and WHI.

The dosage of estrogen may also be a contributing factor in the unfavorable outcome of HRT since it has been shown that certain types of estrogen can decrease heart attacks and stroke in women who have no history of CVD. Conversely, certain levels of estrogen, in combination with progestin, increase the risk of stroke.

The Study

In an effort to isolate the factors involved in the estrogen-CVD connection, and more specifically, to understand what role the dose of the drug might play, the researchers examined whether the adverse effects of ERT were related to the doses being used. For a 60 day period ovariectomized (OVX) mice received the estrogen hormone 17βestrodial (E2), a drug very similar to that used in treating the symptoms of menopause. The mice received one of four dosing levels every day throughout the study period: a very low (VL) dose (0.001 g/d); a low (L) dose (0.42 g/d); a moderate (M) dose (4.2 g/d); or a high (H) dose (28.3 g/d).

The researchers found that:

  • Moderate and high doses of ERT increased the plasma estrogen levels in the mice more than four fold (4.5). This was associated with fluid retention in the uterus, amounts of protein in the urine, and dilated kidneys.

  • By contrast, low doses of E2 restored plasma estrogen to levels similar to the control rats and neither fluid retention nor renal damage was found in this group of mice.

  • Moderate and high doses of E2 also increased atrial natriuretic peptide (ANP), a cardiac hormone that is increased as a marker of severity of heart failure. At low level dosing this did not occur.

  • Overall blood pressure and cardiac function were not changed by ERT at any given dose.

Conclusions

This shows that the size of the estrogen dose may be critical in determining whether ERT leads to cardiovascular or kidney disease, said Dr. Yang, the studys lead researcher. Other factors such as the ratio of estrogen to progestin, the age when the therapy begins and the cardiovascular health of the patient when treatment starts may also be important factors to investigate.


'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
619-525-6202
American Physiological Society
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Medicine will have the unique opportunity to get hands-on experience in an ... school students an immersive experience to gain invaluable, real-life medical skills that are ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to ... analyzed data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical ... the need to operate in a GLP (Good Laboratory Practice) fashion. , With features ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein ... according to a study appearing online in the journal Radiology. , Heart disease and ... increase significantly due to the rapidly aging population. Damage to both organs often occurs ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... -- A new study by a pair of Geisinger Health ... to treat chronic pain is not only ineffective, it ... including death. Palliative care physicians Mellar ... M.D., authored the study which provides a review of ... was published in the December 2016 edition of Current ...
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
Breaking Medicine Technology: